Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. Published

    Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

    Andersen, E. S., Lund, A., Bagger, J. I., Andreasen, C., Grøndahl, M., Deacon, Carolyn F., Hartmann, Bolette, Holst, Jens Juul, Knop, Filip Krag & Vilsbøll, Tina, Aug 2018, In: Diabetes, Obesity and Metabolism. 20, 8, p. 1937-1943

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    Insulinotropic effect of gastric inhibitory polypeptide (GIP) in women with a history of gestational diabetes

    Meier, J. J., Gallwitz, B., Askenas, M., Vollmer, K., Deacon, Carolyn F., Holst, Jens Juul, Schmidt, W. E. & Nauck, M. A., 2005, In: Diabetologia. 48, p. 1872-1881

    Research output: Contribution to journalJournal articleResearch

  3. Published

    Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

    Deacon, Carolyn F., Ahrén, B. & Holst, Jens Juul, 2004, In: Expert Opinion on Investigational Drugs. 13, 9, p. 1091-102 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

    Holst, Jens Juul & Deacon, Carolyn F., 1998, In: Diabetes. 47, p. 1663-1670

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki rats

    Simonsen, L., Pilgaard, S., Carr, R. D., Kanstrup, A. B., Holst, Jens Juul & Deacon, Carolyn F., 2009, In: Hormone and Metabolic Research. 41, 11, p. 851-3 2 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes

    Vardarli, I., Nauck, M. A., Köthe, L. D., Deacon, Carolyn F., Holst, Jens Juul, Schweizer, A. & Foley, J. E., 2011, In: Journal of Clinical Endocrinology and Metabolism. 96, 4, p. 945-954 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.

    Meier, J. J., Nauck, M. A., Kask, B., Holst, Jens Juul, Deacon, Carolyn F., Schmidt, W. E. & Gallwitz, B., 2006, In: World Journal of Gastroenterology. 12, 12, p. 1874-80 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

    Deacon, Carolyn F., 2007, In: Diabetes, Obesity and Metabolism. 9 Suppl 1, p. 23-31 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Incretin-based therapies– review of the physiology, pharmacology and emerging clinical experience

    Martin, J., Deacon, Carolyn F., Gorrell, M. & Prins, J., 2011, In: Internal Medicine Journal (Online). 41, p. 299-307 9 p.

    Research output: Contribution to journalReviewResearchpeer-review

  10. Published

    Incretin hormones and diabetes mellitus

    Vilsbøll, Tina, Knop, Filip Krag, Deacon, Carolyn F. & Holst, Jens Juul, 2009, Therapeutic Strategies in Diabetes. Stehouwer, C. D. A. & Schaper, N. (eds.). Oxford: Clinical Publishing, p. 99-114

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearch

Previous 1...8 9 10 11 12 13 14 15 ...24 Next

ID: 9220